Compare FPI & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FPI | MYGN |
|---|---|---|
| Founded | 2013 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 503.5M | 444.2M |
| IPO Year | 2013 | 1996 |
| Metric | FPI | MYGN |
|---|---|---|
| Price | $9.71 | $5.28 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 7 |
| Target Price | N/A | ★ $7.64 |
| AVG Volume (30 Days) | 385.2K | ★ 1.0M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.14% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | $52,178,000.00 | ★ $771,400,000.00 |
| Revenue This Year | N/A | $6.86 |
| Revenue Next Year | N/A | $5.45 |
| P/E Ratio | $962.00 | ★ N/A |
| Revenue Growth | N/A | ★ 2.33 |
| 52 Week Low | $9.37 | $3.53 |
| 52 Week High | $13.23 | $8.59 |
| Indicator | FPI | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 49.24 | 43.98 |
| Support Level | $9.45 | $4.24 |
| Resistance Level | $9.92 | $5.52 |
| Average True Range (ATR) | 0.16 | 0.29 |
| MACD | 0.03 | -0.13 |
| Stochastic Oscillator | 55.87 | 8.75 |
Farmland Partners Inc owns and seeks to acquire high-quality farmland throughout North America. The company is an internally managed real estate company which owns and contracts farmland and storage facilities located across the United States. Majority of the properties in its portfolio are used to grow primary crops, such as corn, soybeans, wheat, rice and cotton, and rest to produce specialty crops, such as almonds, pictachios, citrus, avacados, strawberies, and edible beans. The company generates its revenues through the rent it receives from its tenants.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.